To solve this problem, scientists have combined anti-PD-1/PD-L1 therapy with other therapeutic strategies, such as Improving cancer immunogenicity and activating anti-cancer immune cells (dendritic cells (DCs), T cells, NK cells, tumor-associated macrophages (TAMs), etc.)and decreasing the number of suppressor immune cells (e.g., T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs)). This evidence concerns the gene CD274 and cancer.